{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"}]}],"title":"ADA positive at any visit (ADA prevalence)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ADA incidence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment-emergent ADA positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment-boosted ADA positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Persistently positive ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Transiently positive ADA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"Blood samples were collected to evaluate the presence of ADAs for T-DXd using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as the percentage of participants who were evaluable for ADA and were treatment-emergent ADA-positive. Treatment-emergent ADA was defined as either treatment-induced (baseline ADA negative, post-baseline ADA positive) or treatment-boosted ADA. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to \\>=2 fold during the study period. Persistently positive was defined as \\>=2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having \\>=1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"OG000","title":"T-DXd"}],"paramType":"NUMBER","populationDescription":"Participants in the ADA-evaluable set consisted of all participants in the Safety Analysis set (SAF- All participants who received at least 1 dose of study treatment) with a non-missing baseline ADA result and at least 1 non-missing post-baseline ADA result.","reportingStatus":"POSTED","timeFrame":"Up to approximately 24 months","title":"Percentage of Participants With Anti-Drug Antibodies (ADA) to T-DXd","type":"SECONDARY","unitOfMeasure":"percentage of participants"}